Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for BRODALUMAB
- Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
- A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
- An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
- A Phase 4 Clinical Study of Brodalumab
- A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
- Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab
- Treatment of Moderate Hidradenitis Suppurativa
- Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis
- Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
- A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
- A Study of KHK4827 in Subjects With Axial Spondyloarthritis (axSpA)
- A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
- Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis
- A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab
- Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
- Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
- Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
- Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
- P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
- Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
Clinical trials list
click for details